Document:

<PAGE>
                                                                    EXHIBIT 10.7

                           DEBENTUREHOLDERS AGREEMENT

         THIS DEBENTUREHOLDERS AGREEMENT (this "Debentureholders Agreement") is
entered into as of December 20, 2002 by and among HALSEY DRUG CO., INC., a
corporation organized and existing under the laws of the State of New York
("Halsey" or the "Company"), and each of the holders of the Company's 5%
Convertible Senior Secured Debentures due March 31, 2006 listed on the signature
page hereto.

         WHEREAS, Halsey is a party to a certain Debenture and Warrant Purchase
Agreement dated as of March 10, 1998, as amended (the "1998 Purchase
Agreement"), with the persons listed on the signature pages thereto and pursuant
to which the Company issued certain 5% Convertible Senior Secured Debentures due
March 31, 2006 (the "1998 Debentures"); and

         WHEREAS, Halsey entered into a certain Debenture and Warrant Purchase
Agreement dated as of May 26, 1999, as amended (the "1999 Purchase Agreement"),
with the persons listed on the signature pages thereto and pursuant to which the
Company issued certain 5% Convertible Senior Secured Debentures due March 31,
2006 (the "1999 Debentures" and together with the 1998 Debentures, the "Existing
Debentures"); and

         WHEREAS, the Company has concurrently herewith entered into a certain
Debenture Purchase Agreement dated as of December __, 2002 (the "2002 Purchase
Agreement"; capitalized terms used herein but not otherwise defined herein shall
have the meanings ascribed thereto in the 2002 Purchase Agreement) with Care
Capital, LLC, Essex Woodlands Health Ventures Fund V and those other persons
listed on the signature pages thereto and pursuant to which the Company proposes
to issue certain 5% Convertible Senior Secured Debentures due March 31, 2006
(the "2002 Debentures" and together with the Existing Debentures, the
"Debentures"); and

         WHEREAS, it is a condition to the completion of the transactions
contemplated pursuant to the 2002 Purchase Agreement that the Company shall have
executed this Debentureholders Agreement providing that the approval of the
holders of the Debentures shall be required as a condition to the Company's
completion of certain material transactions; and

         WHEREAS, the Company and the holders of the Debentures desire to enter
into this Agreement to provide for the approval rights of the holders of the
Debentures as hereinafter provided.

         NOW, THEREFORE, in consideration of the mutual covenants contained
herein and other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the parties hereby agree as follows:
<PAGE>
                  1.       DEBENTUREHOLDER APPROVAL FOR MATERIAL TRANSACTIONS.

                  (a)      Consent of Holders of 2002 Debentures. The Company
hereby covenants and agrees, that so long as any of the 2002 Debentures remain
outstanding, it will not, directly or indirectly, without the prior written
consent of the holders of at least sixty-six and two-thirds percent (66 2/3%) in
the aggregate principal amount of the 2002 Debentures then outstanding, take, or
permit to be taken, any of the following actions or complete, or permit to be
taken, any of the following transactions:

                      (i)      Any modification of the rights of the holders of
                  the 2002 Debentures;

                      (ii)     Any issuance of securities, or the incurrence
                  of indebtedness, by the Company or any Guarantor which rank
                  senior or equal in right of payment to the 2002 Debentures;

                      (iii)    Any declaration or payment of any dividends or
                  distributions on, or redemptions of, any securities ranking
                  junior in priority to the 2002 Debentures, other than
                  dividends or distributions payable in the Company's capital
                  stock or cash interest paid to individual investors in the
                  Existing Debentures;

                      (iv)     (A) A merger, reorganization, consolidation or
                  other business combination involving the Company or any
                  Guarantor, (B) a sale, transfer, lease, license or other
                  disposition of all or substantially all of the assets of the
                  Company or any Guarantor or (C) any other similar
                  extraordinary transaction involving the Company or any
                  Guarantor, in any single transaction or a series of related
                  transactions (the "Extraordinary Transactions"), other than
                  any such transaction where the cash, marketable securities and
                  other liquid consideration received by the holders of the
                  voting stock of the Company in such transaction is at least
                  equal to four (4) times the then applicable conversion price
                  of the 2002 Debentures;

                      (v)      The liquidation, dissolution, commencement of any
                  bankruptcy or other proceeding of the type referred to in
                  Section 12.1(j) of the 2002 Purchase Agreement,
                  recapitalization or reorganization of the Company (in each
                  case whether or not they constitute transactions of the type
                  referred to in Section 1(a)(vi) below); and

                      (vi)     Without limiting the generality of Section
                  1(a)(iv) above, the consummation of a strategic alliance,
                  Extraordinary Transaction, licensing arrangement or other
                  corporate partnering arrangement involving the issuance by the
                  Company or any Guarantor of in excess of ten million dollars
                  ($10,000,000) in equity securities of the Company or any
                  Guarantor.

                  (b)      Consent of Holders of Debentures. Without limiting in
any way the approval rights granted to the holders of the 2002 Debentures in
Section 1(a) above, the Company hereby covenants and agrees, that so long as any
of the Debentures remain outstanding, it will not, directly or indirectly,
without the prior written consent of the holders of at least sixty-six and
two-thirds percent (66 2/3%) in the aggregate principal amount of the Debentures
then

                                       2
<PAGE>
outstanding, take, or permit to be taken, any of the following actions or
complete, or permit to be completed, any of the following transactions:

                      (i)      Any amendment to the Company's Certificate of
                  Incorporation;

                      (ii)     Any declaration or payment of any dividends or
                  distributions on, or redemptions of, the Company's capital
                  stock, other than dividends or distributions payable in the
                  Company's capital stock or cash interest paid to individual
                  investors in the 2002 Debentures, the 1999 Debentures and the
                  1998 Debentures;

                      (iii)    An Extraordinary Transaction; provided,
                  however, that (I) for purposes of calculating the consent of
                  at least sixty-six and two-thirds percent (66 2/3%) in the
                  aggregate principal amount of the Debentures where the cash,
                  marketable securities and other liquid consideration received
                  by the holders of the voting stock of the Company in such
                  Extraordinary Transaction is at least equal to four (4) times
                  the then applicable conversion price of (a) the 2002
                  Debentures, the 2002 Debentures shall be excluded, (b) the
                  1999 Debentures, the 1999 Debentures shall be excluded, and
                  (c) the 1998 Debentures, the 1998 Debentures shall be
                  excluded; and (II) no prior approval or consent of the holders
                  of the Debentures shall be required for any Extraordinary
                  Transaction where the cash, marketable securities and other
                  liquid consideration received by the holders of the voting
                  stock of the Company in such Extraordinary Transaction is at
                  least equal to four (4) times the then highest applicable
                  conversion price of the Debentures;

                      (iv)     The liquidation, dissolution, commencement of any
                  bankruptcy or other proceeding of the type referred to in
                  Section 12.1(j) of the 2002 Purchase Agreement,
                  recapitalization or reorganization of the Company (in each
                  case whether or not they constitute transactions of the type
                  referred to in Section 1(b)(vii) below);

                      (v)      Except as otherwise waived, any issuance of the
                  Company's securities which rank senior or equal in right of
                  payment to the Existing Debentures;

                      (vi)     Any increase in the number of members comprising
                  the Company's Board of Directors above eleven (11); and

                      (vii)    Without limiting the generality of Section
                  1(b)(iii) above, the consummation of a strategic alliance,
                  Extraordinary Transaction, licensing arrangement or other
                  corporate partnering arrangement involving the issuance by the
                  Company of in excess of ten million dollars ($10,000,000) in
                  equity securities of the Company or any Guarantor.

                  2.       AMENDMENT AND WAIVER. Except as otherwise provided
herein, no modification, amendment or waiver of any provision of this
Debentureholders Agreement shall be effective against the Company or the holders
of the Debentures unless such modification, amendment or waiver is approved in
writing by the Company and the holders of not less than fifty-one percent (51%)
of the aggregate principal amount of the Debentures then outstanding; provided
that notwithstanding the foregoing, (a) the prior written consent of each holder
of the 2002 Debentures will be required to amend any payment terms of the 2002
Debentures, (b) the prior

                                       3
<PAGE>
written consent of the holders of at least sixty-six and two-thirds percent
(66 2/3%) in the aggregate principal amount of the 2002 Debentures will be
required to modify, amend or waive any provision of Sections 1(a), 2(a), 2(b)
and 3 of this Debentureholders Agreement and (c) the prior written consent of
the holders of at least sixty-six and two-thirds percent (66 2/3%) in the
aggregate principal amount of the Debentures then outstanding will be required
to modify, amend or waive any provision of Section 1(b) of this Debentureholders
Agreement. The failure of any party to enforce any of the provisions of this
Debentureholders Agreement shall in no way be construed as a waiver of such
provisions and shall not affect the right of such party thereafter to enforce
each and every provision of this Debentureholders Agreement in accordance with
its terms.

                  3.       TERMINATION. This Debentureholders Agreement shall
terminate on the earliest to occur of (a) mutual written agreement of the
parties hereto and (b) the conversion of Debentures into the Company's Common
Stock, or repayment of the Debentures with accrued and unpaid interest, or
combination of the foregoing, such that the aggregate outstanding principal
amount of the Debentures then outstanding is less than five million dollars
($5,000,000).

                  4.       SEVERABILITY. Whenever possible, each provision of
this Agreement shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Debentureholders Agreement is
held to be invalid, illegal or unenforceable in any respect under any applicable
law or rule in any jurisdiction, such invalidity, illegality or unenforceability
shall not affect any other provision or any other jurisdiction, but this
Debentureholders Agreement shall be reformed, construed and enforced in such
jurisdiction as if such invalid, illegal or unenforceable provision had never
been contained herein.

                  5.       ENTIRE AGREEMENT. Except as otherwise expressly set
forth herein, this document, the 2002 Purchase Agreement, the 1998 Purchase
Agreement, as amended pursuant to the Amendment to Debenture and Warrant
Purchase Agreement dated of even date, and the 1999 Purchase Agreement, as
amended pursuant to the Amendment to Debenture and Warrant Purchase Agreement
dated of even date embody the complete agreement and understanding among the
parties hereto with respect to the subject matter hereof and supersede and
preempt any prior understandings, agreements or representations by or among the
parties, written or oral, which may have related to the subject matter hereof in
any way.

                  6.       SUCCESSORS AND ASSIGNS. Except as otherwise provided
herein, this Debentureholders Agreement shall bind and inure to the benefit of
and be enforceable by the Company and its successors and assigns, and the
holders of the Debentures and any subsequent holders of the Debentures and the
respective successors and assigns of each of them, so long as they hold the
Debentures.

                  7.       COUNTERPARTS. This Debentureholders Agreement may be
executed in separate counterparts each of which shall be an original and all of
which taken together shall constitute one and the same agreement.

                                       4
<PAGE>
                  8.       NOTICES. All notices, demands or other communications
to be given or delivered under or by reason of the provisions of this
Debentureholders Agreement will be in writing and will be deemed to have been
given when delivered personally, mailed by certified or registered mail, return
receipt requested and postage prepaid, or sent via a nationally recognized
overnight courier, or sent via facsimile to the recipient accompanied by a
certified or registered mailing. Such notices, demands or other communications
will be sent to the address indicated below:

                  To the Company:

                           Halsey Drug Co., Inc.
                           695 N. Perryville Road
                           Rockford, Illinois 61107
                           Attn: President
                           Fax: 815-399-9710

                  If to the holders of the Debentures:

                           To the address provided
                           on the signature pages to
                           the 1998 Purchase Agreement,
                           1999 Purchase Agreement and
                           2002 Purchase Agreement

or such other address or to the attention of such other person as the recipient
party shall have specified by prior written notice to the sending party. Any
such notice, demand or communication shall be deemed to have been given (a) on
the date of delivery, if delivered personally, (a) on the date of facsimile
transmission, receipt confirmed, (c) one business day after delivery to a
nationally recognized overnight courier service, if marked for next day delivery
or (d) five business days after the date of mailing, if mailed.

                  9.       GOVERNING LAW. This Debentureholders Agreement shall
be governed by, and construed in accordance with, the laws of the State of New
York wherein the terms of this Debentureholder Agreement were negotiated,
excluding to the greatest extent permitted by law any rule of law that would
cause the application of the laws of any jurisdiction other than the State of
New York.

                  10.      JURISDICTION. (a) Each of the parties hereto hereby
irrevocably and unconditionally submits, for itself and its property, to the
nonexclusive jurisdiction of any New York State court or United States Federal
court sitting in New York City, and any appellate court from any thereof, in any
action or proceeding arising our of or relating to this Debentureholders
Agreement to which it is a party, or for recognition or enforcement of any
judgment, and each of the parties hereto irrevocably and unconditionally agrees
that all claims in respect of any such action or proceeding may be heard and
determined in any such New York State court or, to the fullest extent permitted
by law, in such United States Federal court. Each of the parties hereto agrees
that a final judgment in any such action or proceeding shall be conclusive and
may be enforced in other jurisdictions by suit on the right that any party may
otherwise have to bring any

                                       5
<PAGE>
action or proceeding relating to this Debentureholders Agreement in the courts
of any other jurisdiction.

                  (b)      Each of the parties hereto irrevocably and
unconditionally waives, to the fullest extent it may legally and effectively do
so, any objection that it may now or hereafter have to the laying of venue of
any suit, action or proceeding arising out of or in relation to this
Debentureholders Agreement to which it is a party in any such New York State or
United States Federal court sitting in New York City. Each of the parties hereto
hereby irrevocably waives, to the fullest extent permitted by law, the defense
of an inconvenient forum to the maintenance of such action or proceeding in any
such court.

                  11.      WAIVER OF JURY TRIAL. EACH OF THE PARTIES HERETO
HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING
OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR
RELATING TO THIS DEBENTUREHOLDERS AGREEMENT OR THE ACTIONS OF ANY PARTY IN THE
NEGOTIATION, ADMINISTRATION, PERFORMANCE OR ENFORCEMENT THEREOF.

                                       6
<PAGE>
IN WITNESS WHEREOF, the parties hereto have executed this Debentureholders
Agreement as of the date first above written.

                                               Halsey Drug Co., Inc.

                                               By:___________________________

                                               Name:_________________________

                                               Title:________________________

                                       7
<PAGE>
                              2002 DEBENTUREHOLDERS

<TABLE>
<S>                                                  <C>
GALEN PARTNERS III, L.P.                             GALEN PARTNERS INTERNATIONAL, III, L.P.
By: Claudius, L.L.C., General Partner                By: Claudius, L.L.C., General Partner
610 Fifth Avenue, 5th Fl.                            610 Fifth Avenue, 5th Floor
New York, New York 10019                             New York, New York 10020

______________________________________               ___________________________________
By:  Srini Conjeevaram                               By:  Srini Conjeevaram
Its: General Partner                                 Its: General Partner

GALEN EMPLOYEE FUND III, L.P.                        ESSEX WOODLANDS HEALTH
By: Wesson Enterprises, Inc.                         VENTURES V, L.P.
610 Fifth Avenue, 5th Floor                          By: Essex Woodlands Health Ventures V, L.L.C.,
New York, New York 10020                                 its General Partner
                                                     190 South LaSalle Street, Suite 2800
                                                     Chicago, IL 60603

______________________________________               ___________________________________
By:  Bruce F. Wesson                                 By:  Immanuel Thangaraj
Its: General Partner                                 Its: Managing Director

CARE CAPITAL INVESTMENTS II, LP                      BERNARD SELZ
By: Care Capital II, LLC, General Partner            c/o Furman Selz
47 Hulfish Street, Suite 310                         230 Park Avenue
Princeton, NJ 08542                                  New York, New York 10069

______________________________________               ___________________________________
By:  David R. Ramsay
Its: Authorized Signatory

MICHAEL WEISBROT                                     SUSAN WEISBROT
1136 Rock Creek Road                                 1136 Rock Creek Road
Gladwyne, Pennsylvania 19035                         Gladwyne, Pennsylvania 19035

______________________________________               ___________________________________
</TABLE>

                                       8
<PAGE>
<TABLE>
<S>                                                  <C>
GREG WOOD                                            ROGER GRIGGS
c/o D.R. International                               c/o Tom Jennings
7474 No. Figueroa Street                             7300 Turfway Road
Los Angeles, California 90041                        Suite 300
                                                     Florence, KY 41042
______________________________________               ___________________________________

GEORGE E. BOUDREAU
222 Elbow Lane
Haverford, PA 19041

______________________________________
</TABLE>

                                       9
<PAGE>
                            EXISTING DEBENTUREHOLDERS

<TABLE>
<S>                                                  <C>
ORACLE STRATEGIC PARTNERS, L.P.                      GALEN PARTNERS III, L.P.
By: Oracle Strategic Capital L.L.C.,                 By: Claudius, L.L.C., General Partner
General Partner                                      610 Fifth Avenue, 5th Fl.
200 Greenwich Avenue                                 New York, New York 10019
3rd Floor
Greenwich, CT 06830

______________________________________               ___________________________________
By:  Joel Liffmann                                   By:  Srini Conjeevaram
Its: Authorized Agent                                Its: General Partner

GALEN EMPLOYEE FUND III, L.P.                        GALEN PARTNERS INTERNATIONAL, III, L.P.
By: Wesson Enterprises, Inc.                         By: Claudius, L.L.C., General Partner
610 Fifth Avenue, 5th Floor                          610 Fifth Avenue, 5th Floor
New York, New York 10020                             New York, New York 10020

______________________________________               ___________________________________
By:  Bruce F. Wesson                                 By:  Srini Conjeevaram
Its: General Partner                                 Its: General Partner

ALAN SMITH                                           PATRICK COYNE
21 Bedlow Avenue                                     800 Merion Square Road
Newport, Rhode Island 02840                          Gladwyne, PA 19035

______________________________________               ___________________________________

MICHAEL WEISBROT                                     SUSAN WEISBROT
1136 Rock Creek Road                                 1136 Rock Creek Road
Gladwyne, Pennsylvania 19035                         Gladwyne, Pennsylvania 19035

______________________________________               ___________________________________

GREG WOOD                                            DENNIS ADAMS
c/o D.R. International                               120 Kynlyn Road
7474 No. Figueroa Street                             Radnor, Pennsylvania 19312
Los Angeles, California 90041

______________________________________               ___________________________________
</TABLE>

                                       10
<PAGE>
<TABLE>
<S>                                                  <C>
BERNARD SELZ                                         ROBERT W. BAIRD & CO., INC., TTEE
c/o Furman Selz                                      FBO Michael K. Reicher IRA
230 Park Avenue                                      c/o Halsey Drug Co., Inc.
New York, New York 10069                             695 North Perryville Rd.
                                                     Crimson Building #2
                                                     Rockford, Ill. 61107

______________________________________               ___________________________________
                                                     By:  Michael K. Reicher
                                                     Its: Trustee

MICHAEL REICHER                                      PETER CLEMENS
c/o Halsey Drug Co., Inc.                            c/o Halsey Drug Co., Inc.
695 North Perryville Rd.                             695 North Perryville Rd.
Crimson Building #2                                  Crimson Building #2
Rockford, Ill. 61107                                 Rockford, Ill. 61107

______________________________________               ___________________________________

CONNIE REICHER TRUST                                 STEPHANIE HEITMEYER
c/o Halsey Drug Co., Inc.                            17759 Road, Route 66
695 North Perryville Rd.                             Ft. Jennings, Ohio 45844
Crimson Building #2
Rockford, Ill. 61107

______________________________________               ___________________________________
By:  Connie Reicher
Its: Trustee

VARSHA H. SHAH                                       HEMANT K. SHAH
29 Christy Drive                                     29 Christy Drive
Warren, New Jersey 07059                             Warren, New Jersey 07059

______________________________________               ___________________________________

VARSHA H. SHAH AS CUSTODIAN                          VARSHA H. SHAH AS CUSTODIAN
FOR SACHIN H. SHAH                                   FOR SUMEET H. SHAH
29 Christy Drive                                     29 Christy Drive
Warren, New Jersey 07059                             Warren, New Jersey 07059

______________________________________               ___________________________________
By:  Varshah H. Shah                                 By:  Varshah H. Shah
Its: Custodian                                       Its: Custodian
</TABLE>

                                       11
<PAGE>
<TABLE>
<S>                                                  <C>
MICHAEL RAINISCH                                     ILENE RAINISCH
c/o Alvin Rainisch                                   c/o Alvin Rainisch
31 Congressional Road                                31 Congressional Road
Jackson, New Jersey 08527                            Jackson, New Jersey 08527

______________________________________               ___________________________________

KENNETH GIMBEL, IRA ACCOUNT                          KENNETH GIMBEL
FBO KENNETH GIMBEL                                   2455 Montgomery Avenue
2455 Montgomery Avenue                               Highland Park, Ill. 60035
Highland Park, Ill. 60035

______________________________________               ___________________________________
By:___________________________________
Its: Trustee

JESSICA K. CLEMENS                                   JAKE P. CLEMENS
c/o Halsey Drug Co., Inc.                            c/o Halsey Drug Co., Inc.
695 North Perryville Rd.                             695 North Perryville Rd.
Crimson Building #2                                  Crimson Building #2
Rockford, Ill. 61107                                 Rockford, Ill. 61107

______________________________________               ___________________________________

BROOKE EMILY REICHER                                 ALEC JOHN REICHER
c/o Halsey Drug Co., Inc.                            c/o Halsey Drug Co., Inc.
695 North Perryville Rd.                             695 North Perryville Rd.
Crimson Building #2                                  Crimson Building #2
Rockford, Ill. 61107                                 Rockford, Ill. 61107

______________________________________               ___________________________________

COURTNEY PAIGE REICHER                               DEANA REICHER
c/o Halsey Drug Co., Inc.                            c/o Halsey Drug Co., Inc.
695 North Perryville Rd.                             695 North Perryville Rd.
Crimson Building #2                                  Crimson Building #2
Rockford, Ill. 61107                                 Rockford, Ill. 61107

______________________________________               ___________________________________
</TABLE>

                                       12
<PAGE>
<TABLE>
<S>                                                  <C>
MICHAEL K. REICHER II                                TODD ALLEN REICHER
c/o Halsey Drug Co., Inc.                            c/o Halsey Drug Co., Inc.
695 North Perryville Rd.                             695 North Perryville Rd.
Crimson Building #2                                  Crimson Building #2
Rockford, Ill. 61107                                 Rockford, Ill. 61107

______________________________________               ___________________________________
</TABLE>

                                       13
<PAGE>
<TABLE>
<S>                                                  <C>
ROBERT W. BAIRD & CO., INC., TTEE                    ROBERT W. BAIRD & CO., INC., TTEE
FBO Michael Reicher IRA                              FBO Connie Reicher IRA
c/o Halsey Drug Co., Inc.                            c/o Halsey Drug Co., Inc.
695 North Perryville Rd.                             695 North Perryville Rd.
Crimson Building #2                                  Crimson Building #2
Rockford, Illinois 61107                             Rockford, Illinois 61107

______________________________________               ___________________________________
By:  Robert W. Baird                                 By:  Robert W. Baird
Its: Trustee                                         Its: Trustee

MICHAEL REICHER TRUST
c/o Halsey Drug Co., Inc.
695 North Perryville Rd.
Crimson Building #2
Rockford, Illinois 61107

______________________________________
By:  Michael K. Reicher
Its: Trustee
</TABLE>

                                       14<PAGE>
                                                                    EXHIBIT 10.8

                              HALSEY DRUG CO., INC.

                                  AMENDMENT TO
                    DEBENTURE AND WARRANT PURCHASE AGREEMENT

                         DATED AS OF DECEMBER 20th, 2002

         This Amendment to the Debenture and Warrant Purchase Agreement is made
as of this 20th day of December, 2002, by and among Halsey Drug Co., Inc., a New
York corporation (the "Company"), and each of the Purchasers set forth on the
signature page hereto (the "Purchasers").

                                R E C I T A L S :

         WHEREAS, pursuant to that certain Debenture and Warrant Purchase
Agreement dated as of March 10, 1998 (the "Purchase Agreement") executed by the
Company in favor of the Purchasers, the Company issued its 5% Convertible Senior
Secured Debentures due March 15, 2003 (the "Existing Debentures"); and

         WHEREAS, pursuant to a certain Debenture Purchase Agreement dated on or
about December 20, 2002 (the "2002 Purchase Agreement"), proposed to be executed
by the Company in favor of Care Capital LLC, Essex Woodlands Health Ventures and
the other purchasers listed on the signature page thereto, the Company proposes
to issue its 5% Convertible Senior Secured Debentures due March 31, 2006 (the
"New Debentures");

         WHEREAS, as a condition to the investment in the New Debentures to be
made by the Purchasers listed in the 2002 Purchase Agreement (the "New
Holders"), the New Holders have required that the Purchase Agreement be amended
to (i) extend the maturity date of the Existing Debentures from March 15, 2003
to March 31, 2006, (ii) provide that the holders of the Existing Debentures have
veto rights for certain material Company transactions, (iii) provide that the
right of first refusal provided to the holders of the Existing Debentures be
exercisable on a pro rata basis with the New Holders under the 2002 Purchase
Agreement; and (iv) reduce the number of representatives designated by the
holders of the Existing Debentures from three (3) to two (2) commencing with the
second Annual Meeting of Shareholders following the date of this Amendment.

         WHEREAS, as an inducement for the New Holders to make the investment
pursuant to the 2002 Purchase Agreement, the Company and the Purchasers desire
to amend the Purchase Agreement as hereinafter provided;

         NOW, THEREFORE, in consideration of the foregoing recitals and the
covenants herein contained, the parties hereto agree as follows:

         1.       Capitalized terms used herein and not otherwise defined shall
have the meanings provided in the Purchase Agreement.

         2.       Section 1.1 of the Purchase Agreement is hereby amended to
delete Subsection (a) of such Section and replace same with the following:
<PAGE>
                  "(a) its 5% Convertible Senior Secured Debentures due March
                  31, 2006 in the aggregate principal amount of $20,800,000 (the
                  "Debentures"),"

         3.       The Purchase Agreement is hereby amended to provide that the
maturity date of the Debentures shall be March 31, 2006 and that any reference
to a maturity date of March 15, 2003 shall be deemed changed to March 31, 2006.

         4.       The definition of Debentures as contained in Section 1.1 of
the Purchase Agreement is hereby revised to include all 5% Convertible Senior
Secured Debentures having an original maturity date of March 15, 2003 issued
pursuant to the Purchase Agreement, including, without limitation, all 5%
Convertible Senior Secured Debentures issued by the Company to the Purchasers in
satisfaction of interest payments due and payable thereunder. Exhibit A-1 to
this Amendment to the Debenture and Warrant Purchase Agreement sets forth all
Debentures and Warrants issued to the Purchasers pursuant to the Purchase
Agreement through the date hereof.

         5.       Each Purchaser agrees to surrender to the Company each
Debenture instrument issued to such Purchaser as described in Exhibit A-1 to
this Amendment to the Debenture and Warrant Purchase Agreement against the
issuance by the Company of an Amended and Restated 5% Convertible Senior Secured
Debenture of like principal amount due March 31, 2006 in substantially the form
attached as Exhibit B to this Amendment to Debenture and Warrant Purchase
Agreement.

         6.       Section 9.8 of the Purchase Agreement is hereby amended to
delete subsection (a) of such Section and replace same with the following:

                           "(a) The Company agrees to hold meetings of its Board
                  of Directors at least four (4) times a year, at no more than
                  three-month intervals. So long as the Purchasers own any
                  Securities, at each annual meeting of the Company's
                  Stockholders, the Purchasers shall have the right to nominate
                  three (3) designees to be members of the Board of Directors;
                  provided, however, that commencing with the Company's 2004
                  Annual Meeting of Shareholders, the Purchasers shall have the
                  right to nominate two (2) designees to be members of the Board
                  of Directors."

         7.       A new Section 9.18 is hereby added to the Purchase Agreement
as follows:

                  "9.18 Debentureholders Agreement. Each of the Company and the
                  holders of the Debentures has concurrently executed the form
                  of Debentureholders Agreement attached as Exhibit N hereto."

         8.       Section 12.1(c) of the Purchase Agreement is hereby deleted in
its entirety and the following inserted in lieu thereof:

                           "If the Company shall default in the performance of
                  any other material agreement or covenant contained in this
                  Agreement or in any other agreement executed in connection
                  with this Agreement, including that certain Registration
                  Rights Agreement dated December 20, 2002 among the Company,
                  the Purchasers and the other parties thereto, and such default
                  shall not have been remedied to the satisfaction of the Holder
                  or Holders of at least a majority in aggregate principal
                  amount of the Debentures then outstanding, within forty-five
                  (45) days after a Default Notice shall have been given to the
                  Company (the Company to give forwith to all other Holders of
                  Debentures at the time outstanding written notice of the
                  receipt of such Default Notice, specifying the default
                  referred to therein);"

         9.       Article XVI of the Purchase Agreement is hereby deleted in its
entirety and the following inserted in its place:

                                       2
<PAGE>
                                   ARTICLE 16

                  RIGHT OF FIRST REFUSAL: ADDITIONAL INVESTMENT

                  16.1     Right of First Refusal. Each Holder of the
Debentures, Holder of Shares (provided any Debentures remain outstanding and the
Shares received upon conversion have not been sold, transferred or otherwise
disposed of) (the "Common Holder"), holders of the 2002 Debentures (the "2002
Debentureholders") and holders of shares of Common Stock issued upon the
conversion of the 2002 Debentures (provided any 2002 Debentures remain
outstanding and the shares of Common Stock received upon conversion have not
been sold, transferred or otherwise disposed of) (the "New Common Holders")
shall be entitled to the following right of first refusal:

                  (a)      Except in the case of Excluded Securities (as
hereinafter defined), the Company shall not issue, sell or exchange, agree to
issue, sell or exchange, or reserve or set aside for issuance, sale or exchange
(i) any shares of Common Stock, (ii) any other equity security of the Company,
(iii) any debt security of the Company which by its terms is convertible into or
exchangeable for, with or without consideration, any equity security of the
Company, (iv) any security of the Company that is a combination of debt and
equity or (v) any option, warrant or other right to subscribe for, purchase or
otherwise acquire any equity security or any such debt security of the Company
(collectively, the "Equity Securities") unless in each case, the Company shall
have first offered to sell to the holders of Debentures, the Common Holders, the
2002 Debentureholders and the New Common Holders, the Equity Securities, at a
price and on such other terms as shall have been specified by the Company in
writing delivered to each of the Holders of Debentures, the Common Holders, the
2002 Debentureholders and the New Common Holders (the "Offer"), which Offer by
its terms shall remain open and irrevocable for a period of thirty (30) days
from the date it is delivered by the Company to the Holders of Debentures, the
Common Holders, the 2002 Debentureholders and the New Common Holders; provided,
however, that such issuance, sale or exchange of equity securities shall result
in gross proceeds to the Company (whether at the time of issuance or upon
conversion, exercise, or exchange thereof) of an amount in excess of $200,000
(the "Minimum Offering Threshold"). For purposes of computing the Minimum
Offering Threshold, any offering, issuance, sale or exchange of Equity
Securities during any rolling 12 month period shall be aggregated.

                  (b)      Each of the Holders of Debentures, the Common
Holders, the 2002 Debentureholders and the New Common Holders shall have the
right to purchase its pro rata share of the Equity Securities. The "pro rata
share" of each Holder of Debentures, Common Holder, 2002 Debentureholders and
the New Common Holders shall be that amount of the Equity Securities multiplied
by a fraction, the numerator of which is the sum of (i) the Shares underlying
the Debenture held by such person if such person is the holder of a Debenture,
(ii) the number of Shares of Common Stock issued to such Common Holder upon
conversion of a Debenture if such person is a Common Holder, (iii) the number of
shares of Common Stock underlying the 2002 Debentures held by such person if
such person is a 2002 Debentureholder and (iv) the number of shares of Common
Stock issued to a 2002 Debentureholder upon conversion of a 2002 Debenture if
such person is an New Common Holder, and the denominator of which is the sum of
(x) the total number of shares of Common Stock underlying the Debentures issued
pursuant to this Agreement and (y) the total number of shares of Common Stock
underlying the 2002 Debentures.

                  (c)      Notice of the intention of each Holder of a
Debenture, Common Holder, 2002 Debentureholder or New Common Holder to accept,
in whole or in part, an Offer shall be evidenced by a writing signed by such
person, as the case may be and delivered to the Company prior to the end of the
30-day period commencing with the date of such Offer or, if later within ten
(10) days after the delivery of giving of any written notice of a material
change in such Offer, setting forth such portion (specifying number of shares,
principal amount or the like) of the Equity Securities as such person elects to
purchase (the "Notice of Acceptance").

                  (d)      In the event that all Holders of Debentures, Common
Holders, 2002 Debentureholders and New Common Holders do not elect to purchase
all of the Equity Securities, the persons

                                       3
<PAGE>
which have provided notice of their intention to exercise the refusal rights as
provided in subparagraph (c) above shall have the right to purchase, on a pro
rata basis, any unsubscribed portion of the Equity Securities during a period of
ten (10) days following the 30-day period provided in subparagraph (c) above.
Following such additional 10-day period, in the event the Holders of the
Debentures, the Common Holders, 2002 Debentureholders and the New Common Holders
have not elected to purchase all of the Equity Securities, the Company shall
have 90 days from the expiration of the foregoing 40-day period to sell all or
any part of such Equity Securities as to which a Notice of Acceptance has not
been given by any of such persons (the "Refused Securities") to any other person
or persons, but only upon terms and conditions in all material respects,
including without limitation, unit price and interest rates, which are no more
favorable, in the aggregate, to such other person or persons or less favorable
to the Company than those set forth in the Offer. Upon the closing of the sale
to such other person or persons of all of the Refused Securities, which shall
include payment of the purchase price to the Company in accordance with the
terms of the Offer, if the Holders of Debentures, the Common Holders, the 2002
Debentureholders and the New Common Holders have timely submitted a Notice of
Acceptance, it and/or they shall purchase from the Company, and the Company
shall sell to the Holders of Debentures, the Common Holders, 2002
Debentureholders and the New Common Holders, as the case may be, the Equity
Securities in respect of which a Notice of Acceptance was delivered to the
Company, at the terms specified it the Offer. The purchase by the Holders of
Debentures, Common Holders, the 2002 Debentureholders and the New Common Holders
of any Equity Securities is subject in all cases to the preparation, execution
and delivery by the Company and such persons of a purchase agreement and other
customary documentation relating to such Equity Securities as is satisfactory in
form and substance to such persons and each of their respective counsel.

                  (e)      In each case, any Equity Securities not purchased by
the Holders of Debentures, the Common Holders, the 2002 Debentureholders and the
New Common Holders or by a person or persons in accordance with Section 16.1(d)
hereof may not be sold or otherwise disposed of until they are again offered to
such persons under the procedures specified in Section 16.1(a), (b), (c) and (d)
hereof.

                  (f)      The rights of the Holders of Debentures, the Common
Holders, 2002 Debentureholders and the New Common Holders under this Section
16.1 shall not apply to the following securities (the "Excluded Securities"):

                           (i)      Common Stock or options to purchase such
                                    Common Stock, issued to officers, employees
                                    or directors of, or consultants to, the
                                    Company, pursuant to any agreement, plan or
                                    arrangement approved by the Board of
                                    Directors of the Company;

                           (ii)     Common Stock issued as a stock dividend or
                                    upon any stock split or other subdivision or
                                    combination of shares of Common Stock;

                           (iii)    Common Stock issued upon conversion of the
                                    Debentures or the 1999 Debentures, or
                                    exercise of the Warrants or the warrants
                                    issued in connection with the 1999
                                    Debentures, or Common Stock issued upon
                                    conversion of the 2002 Debentures or
                                    exercise of the warrants issued pursuant to
                                    the 2002 Purchase Agreement;

                           (iv)     Common Stock or debentures issued in
                                    satisfaction of interest payments on the
                                    Debentures, the 1999 Debentures and the 2002
                                    Debentures, including the issuance of Common
                                    Stock or Debentures issued in satisfaction
                                    of interest payments on Debenture
                                    instruments issued by the Company in
                                    satisfaction of the interest payments on the
                                    Debentures, the 1999 Debenture and the 2002
                                    Debentures; or

                           (v)      any securities issued for consideration
                                    other than cash pursuant to a merger,
                                    consolidation, acquisition, strategic
                                    alliance or similar business

                                       4
<PAGE>
                                    combination approved by the Board of
                                    Directors and/or at the Company's Annual
                                    Meeting of Shareholders.

                  (g)      Notwithstanding anything to the contrary contained
herein, a Holder of a Debenture, a Common Holder (other than an initial
Purchaser), a 2002 Debentureholders or a New Common Holder (other than an
initial purchaser of a 2002 Debenture) shall not be considered as such for
purposes of this Section 16.1 only, unless such person then holds Debentures or
2002 Debentures with an outstanding principal amount of at least $200,000 or
shares issued upon conversion of at least $200,000 in principal of Debentures or
2002 Debentures or a combination of Debentures or 2002 Debentures and shares of
Common Stock received upon conversion of the Debentures and 2002 Debentures such
that the outstanding principal of the Debentures or 2002 Debentures held by such
person plus the amount of principal of Debentures or 2002 Debentures converted
into shares held by such person equals or exceeds $200,000."

         10.      Subparagraph (a) of Article XIII is hereby amended to add the
following at the end of such Subparagraph:

                  "Notwithstanding the foregoing or anything to the contrary
                  contained in this Article XIII, no amendment to Section 9.18
                  shall be valid unless the same shall be in writing and signed
                  by the Company and the holders of at least 66 2/3% in the
                  aggregate principal amount of the Debenture (including for
                  purposes such calculation the principal amount of those
                  Debentures that at such time have been converted into shares).

         11.      Except as amended above, the terms of the Purchase Agreement
shall remain in full force and effect.

         12.      This Amendment to Debenture and Warrant Purchase Agreement and
the rights of the parties hereunder shall be governed in all respects by laws in
the State of New York wherein the terms of this Amendment were negotiated.

         13.      This Amendment to Debenture and Warrant Purchase Agreement may
be executed in any number of counterparts, each of which shall be original, but
all of which together shall constitute one instrument.

                           [SIGNATURE PAGES TO FOLLOW]

                                       5
<PAGE>
         IN WITNESS WHEREOF, the Company and the Purchasers have caused this
Amendment to be duly executed all on the day and year first above written.

HALSEY DRUG CO., INC.

<TABLE>
<S>                                      <C>
By:__________________________________
   Name:  Michael Reicher
   Title: Chief Executive Officer

PURCHASERS

GALEN PARTNERS III, L.P.                 GALEN PARTNERS INTERNATIONAL, III, L.P.
By: Claudius, L.L.C., General Partner    By: Claudius, L.L.C., General Partner
610 Fifth Avenue, 5th Fl.                610 Fifth Avenue, 5th Floor
New York, New York 10019                 New York, New York 10020

_____________________________________    _______________________________________
By:  Srini Conjeevaram                   By:  Srini Conjeevaram
Its: General Partner                     Its: General Partner

GALEN EMPLOYEE FUND III, L.P.            ALAN SMITH
By: Wesson Enterprises, Inc.             21 Bedlow Avenue
610 Fifth Avenue, 5th Floor              Newport, Rhode Island 02840
New York, New York 10020

_____________________________________    _______________________________________
By:  Bruce F. Wesson
Its: General Partner

PATRICK COYNE                            BERNARD SELZ
800 Merion Square Road                   c/o Furman Selz
Gladwyne, PA 19035                       230 Park Avenue
                                         New York, New York 10069

_____________________________________    _______________________________________

MICHAEL WEISBROT                         SUSAN WEISBROT
1136 Rock Creek Road                     1136 Rock Creek Road
Gladwyne, Pennsylvania 19035             Gladwyne, Pennsylvania 19035

_____________________________________    _______________________________________
</TABLE>

                                       6
<PAGE>
<TABLE>
<S>                                      <C>
GREG WOOD                                DENNIS ADAMS
c/o D.R. International                   120 Kynlyn Road
7474 No. Figueroa Street                 Radnor, Pennsylvania 19312
Los Angeles, California 90041

_____________________________________    _______________________________________

MICHAEL REICHER                          ROBERT W. BAIRD & CO., INC., TTEE
c/o Halsey Drug Co., Inc.                FBO Michael K. Reicher IRA
695 North Perryville Rd.                 c/o Halsey Drug Co., Inc.
Crimson Building #2                      695 North Perryville Rd.
Rockford, Ill. 61107                     Crimson Building #2
                                         Rockford, Ill. 61107

_____________________________________    _______________________________________
                                         By:  Michael K. Reicher
                                         Its: Trustee

CONNIE REICHER TRUST                     PETER CLEMENS
c/o Halsey Drug Co., Inc.                c/o Halsey Drug Co., Inc.
695 North Perryville Rd.                 695 North Perryville Rd.
Crimson Building #2                      Crimson Building #2
Rockford, Ill. 61107                     Rockford, Ill. 61107

_____________________________________    _______________________________________
By:  Connie Reicher
Its: Trustee

VARSHA H. SHAH                           HEMANT K. SHAH
29 Chrissy Drive                         29 Chrissy Drive
Warren, New Jersey 07059                 Warren, New Jersey 07059

_____________________________________    _______________________________________

VARSHA H. SHAH AS CUSTODIAN              VARSHA H. SHAH AS CUSTODIAN
FOR SACHIN H. SHAH                       FOR SUMEET H. SHAH
29 Chrissy Drive                         29 Chrissy Drive
Warren, New Jersey 07059                 Warren, New Jersey 07059

_____________________________________    _______________________________________
By:  Varshah H. Shah                     By:  Varshah H. Shah
Its: Custodian                           Its: Custodian

MICHAEL RAINISCH                         ILENE RAINISCH
c/o Alvin Rainisch                       c/o Alvin Rainisch
</TABLE>

                                       7
<PAGE>
<TABLE>
<S>                                      <C>
300 Flower Lane                          300 Flower Lane
Morganville, New Jersey 07751            Morganville, New Jersey 07751

_____________________________________    _______________________________________

KENNETH GIMBEL, IRA ACCOUNT              KENNETH GIMBEL
FBO KENNETH GIMBEL                       2455 Montgomery Avenue
2455 Montgomery Avenue                   Highland Park, Ill. 60035
Highland Park, Ill. 60035

_____________________________________    _______________________________________
By:__________________________________
Its: Trustee

STEFANIE HEITMEYER
C/o Halsey Drug Co., Inc.
695 North Perryville Rd.
Crimson Building #2
Rockford, Ill. 61107

_____________________________________
</TABLE>

                                       8
<PAGE>
<TABLE>
<S>                                      <C>
ROBERT W. BAIRD & CO., INC., TTEE        ROBERT W. BAIRD & CO., INC., TTEE
FBO Michael Reicher IRA                  FBO Connie Reicher IRA
c/o Halsey Drug Co., Inc.                c/o Halsey Drug Co., Inc.
695 North Perryville Rd.                 695 North Perryville Rd.
Crimson Building #2                      Crimson Building #2
Rockford, Illinois 61107                 Rockford, Illinois 61107

_____________________________________    _______________________________________
By:  Robert W. Baird                     By:  Robert W. Baird
Its: Trustee                             Its: Trustee

MICHAEL REICHER TRUST
c/o Halsey Drug Co., Inc.
695 North Perryville Rd.
Crimson Building #2
Rockford, Illinois 61107

_____________________________________
By:  Michael K. Reicher
Its: Trustee
</TABLE>

                                       9
<PAGE>
                                  EXHIBIT A-1

                            LIST OF DEBENTURE HOLDERS

                                       10
<PAGE>
                                    EXHIBIT B

                          FORM OF AMENDED AND RESTATED
                     5% CONVERTIBLE SENIOR SECURED DEBENTURE

                                       11
<PAGE>
                                    EXHIBIT N

                            DEBENTUREHOLDER AGREEMENT

                                       12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00046-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00046-of-00352.parquet"}]]